SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep pullback to multi-month lows dominates discussion, with traders debating whether macro headwinds, ETF outflows and competing demand for capital are driving the weakness; speculation about exchange-related selling also appears but is unconfirmed. Bears see further downside, while dip buyers argue the selloff is oversold and key support may hold.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline alongside a broader crypto selloff, with traders pointing to Bitcoin weakness and market-wide risk aversion, dominates the discussion. Bears warn that support may give way, while bullish holders are buying the dip and arguing the drop is an accumulation opportunity.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadias NUPLAZID formulation-patent appeal is the main focus, with traders debating whether the appellate court will uphold favorable lower-court rulings or threaten the drugs long-term exclusivity. The legal uncertainty has fueled sharp selling and a rebound, while bullish voices point to growth in DAYBUE and NUPLAZID as support for the business beyond the court decision.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the FDAs PDUFA decision on ivonescimab for EGFR-mutated lung cancer, with traders treating the outcome as a high-stakes binary event. The debate centers on the drugs strong progression-free-survival results and favorable but not statistically significant overall-survival data versus the FDAs stated need for significant survival evidence, leaving approval, a delay, or a rejection in question.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,964,197.93006099. The last known price of Zcash is 932.62986485 USD and is down -2.50 over the last 24 hours. It is currently trading on 670 active market(s) with $1,142,095,783.67 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention after a sharp pullback from its recent rally, with traders debating whether the decline marks capitulation or leaves room for further losses. Some are buying the dip and citing ZECs privacy-focused appeal, while bears point to broad crypto selling and liquidation pressure.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Attention centers on NXC-201s NEXICART-2 results and upcoming ASH presentations, with traders highlighting strong complete-response and safety data as support for a future BLA. That optimism is balanced by frustration over the stocks decline, the recent financing and a pushed-out filing timeline, alongside speculation about short interest and whether the weakness reflects broader biotech sentiment.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a steep, extended decline alongside weakness across the crypto market, with traders pointing to fresh lows and fading interest. The discussion is largely bearish, with many expecting further losses, while some holders are buying the dip and citing possible technical signs of a bottom.

Pinterest, Inc. engages in the operation of an AI-powered visual search and discovery platform. It enables users to find inspiration, curate ideas, search for products, and discover content through visual recommendations. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is under pressure after Q3 results missed revenue expectations and its softer Q4 outlook prompted analyst target cuts, despite record user growth. Traders debate whether its growing audience and AI-powered shopping and ad products can drive stronger monetization, while skeptics question ad pricing and whether browsing converts to purchases.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,704,555,155.77490568 with 589,238,111,425,239.3151592 in circulation. The last known price of Shiba Inu is 0.00000425 USD and is down -2.37 over the last 24 hours. It is currently trading on 1128 active market(s) with $56,784,935.49 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIB is drawing attention amid a prolonged, choppy decline, with repeated chart commentary describing bearish structure and consolidation. Holders are split between hoping for a meme-coin rebound and expressing frustration over weak performance, limited utility, and stalled token burns.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP volatility and reports of continued spot-ETF inflows are driving attention, alongside speculation that regulatory clarity could support institutional demand. Bullish holders point to fund buying and XRPs adoption prospects, while skeptics question its utility and price momentum; some traders also appear confused between the Bitwise fund and the XRP token.

statis crypto Watchlist

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Johntrades2

john donni